The current market price of Nippon India NIFTY Pharma ETF Growth Plan is ₹25.53. ETF prices fluctuate during market hours based on demand, supply, and movements in the underlying index or assets.

Nippon India NIFTY Pharma ETF Growth Plan by Nippon Life India Asset Management Limited is an Equity ETF with a passive objective to track Nifty Pharma TRI in index proportions The fund employs full passive replication against the Nifty Pharma TRI, maintaining tight tracking with a low tracking error of 0.0% and systematic weight alignment to index constituents and discipline Portfolio comprises 21 constituents dominated by Pharmaceuticals & Biotechnology at 99.9%, with top five holdings concentrated: Sun Pharma 21.3%, Divi's Laboratories 9.7%, Cipla 9.4%, Dr. Reddy's 9.4%, Lupin 6.6% approximately Performance over the past year shows 1Y: +4.2% while tracking error remains minimal at 0.0%, indicating close benchmark replication and near-identical pharmac sector returns to index metrics with limited drift Operationally AUM stood at ₹1007.5 Cr as on Jan 2026 with monthly average ₹1007.0 Cr, expense ratio 0.2%, minimal cash 0.06%, manager Jitendra Tolani since Feb 2025, 19 years experience

Nippon India NIFTY Pharma ETF Growth Plan is designed to track Nifty Pharma TRI, allowing investors to gain exposure to its underlying securities through a single investment.

The expense ratio of Nippon India NIFTY Pharma ETF Growth Plan is 0.21%. This represents the annual fee charged by the fund house for managing the ETF and is deducted from the fund’s assets.

The Assets Under Management (AUM) of Nippon India NIFTY Pharma ETF Growth Plan is approximately ₹1,007.47. AUM reflects the total market value of assets managed by the ETF and is often used as an indicator of fund size and liquidity.

Nippon India NIFTY Pharma ETF Growth Plan is classified under the Very High risk category. The risk level depends on the volatility of the underlying index, market conditions, and asset composition of the ETF.

The tracking error of Nippon India NIFTY Pharma ETF Growth Plan is 0.02%. Tracking error measures how closely the ETF’s performance matches its benchmark index over time.

Nippon India NIFTY Pharma ETF Growth Plan has a dividend yield of 0.70%. Dividend treatment depends on the ETF structure and fund house policy.

Based on available data, Nippon India NIFTY Pharma ETF Growth Plan has delivered the following returns: 1-year return: 14.15%. 3-year return: 14.15%. 5-year return: 14.15%. Past performance does not guarantee future results.

Before investing in Nippon India NIFTY Pharma ETF Growth Plan, investors generally consider the underlying index, expense ratio, tracking error, risk profile, liquidity, and how the ETF fits within their overall portfolio strategy.